Trials / Approved For Marketing
Approved For MarketingNCT04323761
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remdesivir | Intravenous infusion administered over a 30 to 120 minute period |
Timeline
- First posted
- 2020-03-27
- Last updated
- 2020-11-13
Locations
272 sites across 27 countries: United States, Australia, Austria, Belgium, Canada, Cyprus, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT04323761. Inclusion in this directory is not an endorsement.